Skip to main content
BBIO
NASDAQ Life Sciences

KKR Sells 5M BridgeBio Shares at $78 in $390M Secondary Offering

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$79.83
Mkt Cap
$15.876B
52W Low
$46.81
52W High
$93.415
52W Position info
71% above low
Off High info
15% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

BBIO sits 71% above its 52-week low of $46.81 on light trading volume (0.4× avg).

Summary

KKR is selling 5 million BridgeBio shares at $78.00 each in a $390 million secondary offering, reducing its stake from 7.3% to 4.7%. The company receives no proceeds.


Key Events · Financing and Capital Events · BBIO

  • KKR Sells 5M Shares

    KKR Genetic Disorder L.P. is selling 5,000,000 shares at $78.00 per share, totaling $390 million. The company receives no proceeds.

  • Stake Drops Below 5%

    KKR's beneficial ownership falls from 14,232,739 shares (7.3%) to 9,232,739 shares (4.7%), crossing below the 5% reporting threshold.

  • Priced at 2.3% Discount

    The offering price of $78.00 is 2.3% below the last close of $79.83, indicating a modest discount to market.

  • Underwriters and Conflict

    William Blair, Goldman Sachs, and KKR Capital Markets are underwriting. KKR Capital Markets has a conflict of interest under FINRA Rule 5121 because KKR affiliates are selling stockholders.


Analysis · BBIO · Life Sciences

KKR Genetic Disorder L.P. is selling 5 million shares of BridgeBio at $78.00 per share, a 2.3% discount to the last close of $79.83. The company receives no proceeds — this is a secondary sale by an existing holder. KKR's stake drops from 7.3% to 4.7%, crossing below the 5% reporting threshold. The offering is priced near market, suggesting orderly distribution rather than distress, but the overhang of a large block sale can pressure the stock in the near term.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BBIO was trading at $79.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $46.81 to $93.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $76.03 info
Change: +$5.34 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $76.03 info
Change: +$4.59 (+6%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $76.03 info
Change: +$5.36 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $76.03 info
Change: +$10.28 (+16%) info
Market Cap: $14.811B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $76.03 info
Change: +$10.68 (+16%) info
Market Cap: $14.811B info